Latest Parexel Stories

BOSTON, June 17, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day on Wednesday, June 26, 2013, from 8:30 a.m. to 12:30 p.m. (EDT). All interested parties are invited to listen as Chairman and Chief Executive Officer Josef von Rickenbach, Chief Financial Officer Jim Winschel and five additional members of the executive team provide a...

Industry veteran brings 18 years of global finance, operations, and strategic corporate development experience to PAREXEL BOSTON, June 13, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Ingo Bank has been appointed Senior Vice President and will become Chief Financial Officer on September 1, after fiscal year-end audited financial statements are filed. He joins PAREXEL on July 8 from...

BOSTON, June 11, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Wells Fargo Healthcare Conference in Boston. James Winschel, Sr. Vice President and Chief Financial Officer, will be making a presentation on PAREXEL and discussing business developments at 10:35 a.m. ET on Tuesday, June 18, 2013. A live webcast of the presentation will be available through the"Investors" section of PAREXEL's website at...

NEW YORK, June 7, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Life Technologies Corporation (NASDAQ: LIFE), PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), Genomic Health, Inc. (NASDAQ: GHDX), and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI). Today's readers may access these reports free of charge - including...

BOSTON, June 4, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the William Blair Growth Stock Conference in New York. Josef von Rickenbach, Chairman and Chief Executive Officer, will be making a presentation on PAREXEL and discussing business developments at 10:40 a.m. ET on Wednesday, June 12, 2013. PAREXEL will also be presenting at the Goldman Sachs Healthcare Conference in Ranchos Palos Verdes, CA. James...

BOSTON, May 23, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the Jefferies Healthcare Conference in New York. James Winschel, Sr. Vice President and Chief Financial Officer, will be making a presentation on PAREXEL and discussing business developments at 1:30 p.m. ET on Monday, June 3, 2013. A live webcast of the presentation will be available through the "Investors" section of PAREXEL's website at...

Edgemont enhances its position as the leading M&A advisor to clinical research site companies NEW YORK, May 15, 2013 /PRNewswire/ -- Edgemont Capital Partners ("Edgemont"), a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical Research ("Vince and Associates") in its sale to Altasciences Group. Vince and Associates manages complex early development clinical...

- Service revenue of $454.5 million, up 27.7% year-over-year BOSTON, April 30, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) today reported financial results for the third quarter of Fiscal Year 2013, which ended on March 31, 2013. For the three months ended March 31, 2013 consolidated service revenue increased by 27.7% to $454.5 million compared with $356.0 million in the prior year period. Excluding the negative impact from foreign exchange...

BOSTON, April 30, 2013 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL), a global clinical research organization, announced that today the Company acquired all of the outstanding equity securities of the HERON Group LTD ("HERON"), a life sciences consultancy which provides evidence-based commercialization services to support biopharmaceutical companies throughout the lifecycle of their products. HERON has expertise and methodologies spanning a wide range of services,...

Award highlights success of innovative strategic partnership at 22nd Annual Partnerships in Clinical Trials conference in Orlando, FL BOSTON, April 24, 2013 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced it has been named a recipient of the 2013 "Partnership Pioneers of the Year" award in recognition of its innovative strategic partnership with Pfizer and ICON. Given by the advisory board of the...